Key result
Endovascular therapy reduces 6-month post-thrombotic syndrome severity by ~2 points vs. standard care.
Why the study?
Does endovascular therapy (iliac-vein stent placement and enhanced antithrombotic therapy) added to standard care reduce post-thrombotic syndrome severity at 6 months compared with standard care alone in patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction?
RCT (n=225)
Open-label, assessor-blinded
1:1 web-based central randomization, stratified by clinical center, presence of open venous ulcer, and normal/abnormal common femoral vein on ultrasound
Yes
Does endovascular therapy (iliac-vein stent placement and enhanced antithrombotic therapy) added to standard care reduce post-thrombotic syndrome severity at 6 months compared with standard care alone in patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction?
In patients with moderate-to-severe post-thrombotic syndrome and iliac vein obstruction, adding endovascular iliac vein stenting and enhanced antithrombotic therapy to standard care significantly reduces symptom severity and substantially improves quality of life at 6 months, at the cost of increased mostly non-major bleeding.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Many patients with PTS suffer in silence because few physicians are aware of this complication or know how to effectively treat it. This study suggests that even severe PTS is, in fact, a treatable condition in many patients.”
“In addition, both when we were looking at venous symptoms and health, and looking at patient's overall health status, the patients who were stented [had] improved health-related quality of life demonstrated by higher scores on questionnaires. The size of the differences are pretty robust relative to what we know about the scales.”
“Our findings show that carefully performed endovascular therapy, supported by evidence-based medical management, can meaningfully reduce symptoms and improve daily functioning for patients with long-term blockages of important veins after a blood clot.”
Endovascular therapy may be considered for moderate-to-severe post-thrombotic syndrome with iliac obstruction; first RCT evidence of reduced severity and improved quality of life.
BACKGROUND: Post-thrombotic syndrome is common after deep-vein thrombosis and can cause severe symptoms involving the limbs that impair patients' activity and quality of life. Endovascular therapy can eliminate chronic venous obstruction and is hypothesized to reduce the severity of post-thrombotic syndrome. METHODS: We randomly assigned 225 patients with moderate or severe post-thrombotic syndrome and imaging-confirmed iliac-vein obstruction to receive endovascular therapy (iliac-vein stent placement and enhanced antithrombotic therapy) plus standard post-thrombotic syndrome care or standard post-thrombotic syndrome care alone. The severity of post-thrombotic syndrome at 6 months (the primary outcome) was assessed with the validated Venous Clinical Severity Score (VCSS) tool (scores range from 0 to 30, with higher scores indicating more severe post-thrombotic syndrome) by evaluators who were unaware of the group assignments. Key secondary outcomes included venous disease-specific and overall quality of life. RESULTS: At 6 months, the severity of post-thrombotic syndrome was lower in the endovascular-therapy group than in the no-endovascular-therapy group (mean [±SD] VCSS, 8.1±5.1 vs. 10.0±4.9; adjusted difference, -2.0; P = 0.001). Venous disease-specific quality of life as assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire was better in the endovascular-therapy group than in the no-endovascular-therapy group at 6 months (adjusted difference, 14.5 points; P<0.001), as was overall quality of life as assessed with the Medical Outcomes Study 36-Item Short-Form Health Status Survey physical component summary score (adjusted difference, 6.1 points; P<0.001); scores on both tools range from 0 to 100. Through 6 months, bleeding was more common in the endovascular-therapy group than in the no-endovascular-therapy group (in 11.6% vs. 3.6% of the patients; P = 0.03). CONCLUSIONS: Among patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction, endovascular therapy led to less severe post-thrombotic syndrome and better health-related quality of life than standard care over a 6-month period but with a higher risk of bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Vedantham et al. (2026) conducted an RCT in Moderate or severe post-thrombotic syndrome with iliac-vein obstruction (n=225). Endovascular therapy (iliac-vein stent placement and enhanced antithrombotic therapy) plus standard post-thrombotic syndrome care vs. Standard post-thrombotic syndrome care alone (individualized compression therapy, risk-appropriate anticoagulation, lifestyle guidance, and ulcer care) was evaluated on Severity of post-thrombotic syndrome at 6 months assessed with the Venous Clinical Severity Score (VCSS, range 0-30) (MD -2.0, 95% CI -3.2 to -0.8, p=0.001). Endovascular therapy reduced 6-month post-thrombotic syndrome severity on the VCSS compared with standard care alone.
Synapse has enriched 10 related papers. Consider them for comparative context: